Short abstract
Possible role for COX‐2 in the pathophysiology of CF
Keywords: cystic fibrosis, nasal polyp, cyclo‐oxygenase, COX‐1, COX‐2
Lung disease in cystic fibrosis (CF) continues to be the major cause of morbidity and mortality, with the mechanisms whereby the biochemical defect causes lung disease receiving considerable attention. CF is caused by mutations in a 230 kB gene located on chromosome 7 which codes for the cystic fibrosis transmembrane conductance regulator (CFTR).1 CFTR functions in the main as a cAMP regulated chloride channel in epithelial and glandular structures.2 It has long been recognised that the abnormal chloride secretion by bronchial epithelial cells in CF predisposes to the development of bronchial damage and inflammation. The mechanism is under debate, but altered biochemical constituents of airway surface liquid,3,4,5 function of the mucociliary escalator,6 and the function of antibacterial defence molecules such as defensins6 are all thought to play a part. What is less clear is whether inflammation itself can feed back to further compromise the abnormalities in chloride transport leading to an amplificatory cycle of lung destruction. Studies of nasal potential difference in patients with CF have shown that there is a range in the severity of chloride flux reduction.7,8
Lipid mediators such as prostanoids have an important role in regulating inflammation in most tissues including the lung. Prostanoids are produced from membrane phospholipids by a three step reaction involving arachidonic acid release via phospholipase A2, conversion of arachidonic acid into PGH2 by cyclo‐oxygenase (COX), followed by its conversion to terminal prostaglandins such as PGE2 by specific synthases and isomerases. COX exists in three isoforms:9 COX‐1 is constitutively expressed;10 COX‐2 is inducible and therefore implicated in many inflammatory and malignant diseases;11,12 and a further enzyme, COX‐3, has recently been described whose function is less well defined.13 Previous studies have shown that the levels of prostanoids such as PGE2, PGF2, PGF1, and thromboxane B2 are raised in primary cultures of epithelial cells from the CF airway,14 suggesting that they may play a part in the pathogenesis of CF. Further evidence to suggest that prostanoids have an important pro‐inflammatory role in CF is provided by clinical trials which have shown that the broad spectrum COX inhibitor ibuprofen can delay the progression of CF lung disease.15
Several questions are raised by these findings.
What is the mechanism of increased prostanoid release and what is their role in regulating CF disease?
How might increased COX‐2 expression occur in CF?
How does an increase in COX‐2 expression contribute to CF pathophysiology?
What are the implications of these findings?
What is the mechanism of increased prostanoid release and what is their role in regulating CF disease?
In this issue of Thorax Roca‐Ferrer and colleagues16 investigate the expression of COX isoforms in the nasal epithelium of patients with CF. The most striking feature of their studies was that COX‐2 protein was strongly expressed in CF but not in non‐CF polyps or in normal mucosa. Furthermore, upregulation of COX‐2 protein was more marked than COX‐2 mRNA, suggesting possible alterations in transcriptional and post‐transcriptional regulation. COX‐1 protein was also upregulated in CF, but to a lesser degree as it was strongly expressed in normal mucosa and non‐CF polyps. COX‐1 mRNA was also slightly upregulated. These results suggest that the marked upregulation of COX‐2 is likely to be responsible for the increased prostanoid levels found by others in CF.
How might increased COX‐2 expression occur in CF?
There is currently no evidence that alterations in CFTR can directly regulate COX‐2, whereas COX‐2 upregulation is commonly seen in inflammatory microenvironments such as the CF lung. Perhaps a more plausible explanation is that bacterial products and/or pro‐inflammatory cytokines in the inflamed CF lung are responsible for inducing COX‐2. Bacterial lipopolysaccaride can induce COX‐2 in T84 gut epithelial cells,17 mouse neurons,18 and macrophages.19 We and others have shown that IL‐1β, which is increased in CF,20 can induce COX‐2 in airway epithelial cells.21 While the results reported by Roca‐Ferrer are interesting, a key question is whether or not similar changes in COX expression are found in bronchial epithelium.
How does an increase in COX‐2 expression contribute to CF pathophysiology?
One hypothesis that we have been pursuing in our laboratory is that COX‐2 products can regulate CFTR mediated chloride flux across the airway epithelium. In experiments in a Calu‐3 bronchial epithelial cell line which expresses functional CFTR channels in bronchial epithelial cells, we found that chronic exposure to IL‐1β significantly impaired cAMP accumulation and chloride efflux in response to PGE2.21 This effect was accompanied by COX‐2 induction and was abolished if cells were treated with selective COX‐2 inhibitors. Mechanistic studies showed that this effect was mediated by downregulation of EP4 prostanoid receptors and adenylyl cyclase. The fact that adenylyl cyclase was downregulated suggests that the response to other receptors linked to this pathway would also be impaired. Collectively, these observations suggest that IL‐1β impairs cAMP and chloride responses via an autocrine loop involving COX‐2 induction and production of endogenous PGE2. This might further impair the already defective chloride flux in CF and exacerbate the abnormalities in the composition of the airway surface liquid that occur as a result of CFTR dysfunction, promoting further infection and inflammation.
What are the implications of these findings?
The COX inhibitor ibuprofen has been shown to delay the progression of lung disease in children with CF.15 Ibuprofen is a non‐selective COX inhibitor which acts on both COX‐1 and COX‐2. Studies in healthy volunteers showed that it inhibits 71.4% of COX‐2 activity and 88.7% of COX‐1 activity.22 Selective COX‐2 inhibitors might be more effective, but the recent worries concerning the cardiovascular safety of this class of drugs tempers enthusiasm. Interestingly, glucocorticoids prevent COX‐2 induction and this may contribute to their beneficial effects in CF. Further work is needed to examine how inflammatory genes such as COX are regulated in CF, and how these changes impact on disease pathophysiology.
Footnotes
Competing interests: none declared.
References
- 1.Riordan J R, Rommens J M, Kerem B.et al Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 19892451066–1073. [DOI] [PubMed] [Google Scholar]
- 2.Vankeerberghen A, Cuppens H, Cassiman J J. The cystic fibrosis transmembrane conductance regulator: an intriguing protein with pleiotropic functions. J Cyst Fibros 2002113–29. [DOI] [PubMed] [Google Scholar]
- 3.Zabner J, Smith J J, Karp P H.et al Loss of CFTR chloride channels alters salt absorption by cystic fibrosis airway epithelia in vitro. Mol Cell 19982397–403. [DOI] [PubMed] [Google Scholar]
- 4.Widdicombe J H, Bastacky S J, Wu D X.et al Regulation of depth and composition of airway surface liquid. Eur Respir J 1997102892–2897. [DOI] [PubMed] [Google Scholar]
- 5.Matsui H, Grubb B R, Tarran R.et al Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998951005–1015. [DOI] [PubMed] [Google Scholar]
- 6.Smith J J, Travis S M, Greenberg E P.et al Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 199685229–236. [DOI] [PubMed] [Google Scholar]
- 7.Thomas S R, Jaffe A, Geddes D M.et al Pulmonary disease severity in men with deltaF508 cystic fibrosis and residual chloride secretion. Lancet 1999353984–985. [DOI] [PubMed] [Google Scholar]
- 8.Bronsveld I, Mekus F, Bijman J.et al Chloride conductance and genetic background modulate the cystic fibrosis phenotype of Delta F508 homozygous twins and siblings. J Clin Invest 20011081705–1715. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Xie W L, Chipman J G, Robertson D L.et al Expression of a mitogen‐responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991882692–2696. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Vane J. Towards a better aspirin. Nature 1994367215–216. [DOI] [PubMed] [Google Scholar]
- 11.DeWitt D L. Prostaglandin endoperoxide synthase: regulation of enzyme expression. Biochim Biophys Acta 19911083121–134. [DOI] [PubMed] [Google Scholar]
- 12.Fu J Y, Masferrer J L, Seibert K.et al The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 199026516737–16740. [PubMed] [Google Scholar]
- 13.Chandrasekharan N V, Dai H, Roos K L.et al COX‐3, a cyclooxygenase‐1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 20029913926–13931. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Widdicombe J H, Ueki I F, Emery D.et al Release of cyclooxygenase products from primary cultures of tracheal epithelia of dog and human. Am J Physiol 1989257L361–L365. [DOI] [PubMed] [Google Scholar]
- 15.Konstan M W, Byard P J, Hoppel C L.et al Effect of high‐dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995332848–854. [DOI] [PubMed] [Google Scholar]
- 16.Roca‐Ferrer J, Pujols L, Gartner S.et al Upregulation of COX‐1 and COX‐2 in nasal polyps in cystic fibrosis. Thorax 200661592–596. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Korhonen R, Kosonen O, Korpela R.et al The expression of COX2 protein induced by Lactobacillus rhamnosus GG, endotoxin and lipoteichoic acid in T84 epithelial cells. Lett Appl Microbiol 20043919–24. [DOI] [PubMed] [Google Scholar]
- 18.Breder C D, Saper C B. Expression of inducible cyclooxygenase mRNA in the mouse brain after systemic administration of bacterial lipopolysaccharide. Brain Res 199671364–69. [DOI] [PubMed] [Google Scholar]
- 19.Tordjman C, Coge F, Andre N.et al Characterisation of cyclooxygenase 1 and 2 expression in mouse resident peritoneal macrophages in vitro: interactions of non‐steroidal anti‐inflammatory drugs with COX2. Biochim Biophys Acta 19951256249–256. [DOI] [PubMed] [Google Scholar]
- 20.Osika E, Cavaillon J M, Chadelat K.et al Distinct sputum cytokine profiles in cystic fibrosis and other chronic inflammatory airway disease. Eur Respir J 199914339–346. [DOI] [PubMed] [Google Scholar]
- 21.Clayton A, Holland E, Pang L.et al Interleukin‐1β differentially regulates β2 adrenoreceptor and prostaglandin E2‐mediated cAMP accumulation and chloride efflux from Calu‐3 bronchial epithelial cells. Role of receptor changes, adenylyl cyclase, cyclo‐oxygenase 2, and protein kinase A. J Biol Chem 200528023451–23463. [DOI] [PubMed] [Google Scholar]
- 22.Van Hecken A, Schwartz J I, Depre M.et al Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX‐2 versus COX‐1 in healthy volunteers. J Clin Pharmacol 2000401109–1120. [PubMed] [Google Scholar]